The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Open accessAbstract
BACKGROUND: The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly. We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study. METHODS: A total of 1493 patients with schizophrenia were recruited at 57 U.S. sites and randomly assigned to receive olanzapine (7.5 to 30 mg per day), perphenazine (8 to 32 mg per day), quetiapine (200 to 800 mg per day), or risperidone (1.5 to 6.0 mg per day) for up to 18 months. Ziprasidone (40 to 160 mg per day) was included after its approval by the Food and Drug Administration. The primary aim was to delineate differences in the overall effectiveness of these five treatments. RESULTS: Overall, 74 percent of patients discontinued the study medication before 18 months (1061 of the 1432 patients who received at least one dose): 64 percent of those assigned to olanzapine, 75 percent of those assigned to perphenazine, 82 percent of those assigned to quetiapine, 74 percent of those assigned to risperidone, and 79 percent of those assigned to ziprasidone. The time to the discontinuation of treatment for any cause was significantly longer in the olanzapine group than in the quetiapine (P<0.001) or risperidone (P=0.002) group, but not in the perphenazine (P=0.021) or ziprasidone (P=0.028) group. The times to discontinuation because of intolerable side effects were similar among the groups, but the rates differed (P=0.04); olanzapine was associated with more discontinuation for weight gain or metabolic effects, and perphenazine was associated with more discontinuation for extrapyramidal effects. CONCLUSIONS: The majority of patients in each group discontinued their assigned treatment owing to inefficacy or intolerable side effects or for other reasons. Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone. Olanzapine was associated with greater weight gain and increases in measures of glucose and lipid metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An example of an early precursor to the SMART is the Clinical Antipsychotics Trial of Intervention Effectiveness (CATIE) [54] in chronic schizophrenia.”
From Introduction to SMART designs for the development of adaptive interventions: with application to weight loss research (2014) · cites this paper as [54]
In the citing paper
“In schizophrenia, for example, recent studies have shown that since the introduction of second-generation antipsychotics, treatment efficacy has only marginally improved over traditional dopamine D-2 antagonists, which were introduced 50 years ago (Lieberman et al., 2005”
From Neuronal Dynamics and Neuropsychiatric Disorders: Toward a Translational Paradigm for Dysfunctional Large-Scale Networks (2012) · cites this paper as Lieberman et al., 2005
In the citing paper
“While effective in reducing the positive symptoms, the cognitive dysfunctions and negative symptoms, two major determinants for outcome and level of functioning, remained unchanged in the large majority of patients.”
From Neuronal Dynamics and Neuropsychiatric Disorders: Toward a Translational Paradigm for Dysfunctional Large-Scale Networks (2012) · cites this paper as Lieberman et al., 2005
In the citing paper
“Over the last 50 years, the pharmacological therapy of schizophrenia was based mainly on the dopamine hypothesis and made little progress (Lieberman et al., 2005”
From Neuronal Dynamics and Neuropsychiatric Disorders: Toward a Translational Paradigm for Dysfunctional Large-Scale Networks (2012) · cites this paper as Lieberman et al., 2005
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Tunis (2003) · doi:10.1001/jama.290.12.1624 · Cited by 1,724
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Geddes, J. R., Freemantle, N., Harrison, P. J., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,056
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,022
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Self-citationLeucht, S., Pitschel‐Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 795
Flagged first, then by citations
Cited by
Sorted by citations
Items 1,001–1,049 of 1,049
Discontinuing Psychiatric Medications: A Survey of Long-Term Users
Ostrow, L., Jessell, L., Hurd, M., Darrow, S. M., & Cohen, D. (2017) · Psychiatric Services · doi:10.1176/appi.ps.201700070 · Cited by 62
Hughes, S., & Cohen, D. (2011) · Journal of Medical Internet Research · doi:10.2196/jmir.1716 · Cited by 57
Grossberg, G. T., Pejović, V., Miller, M. L., & Graham, S. M. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000200013 · Cited by 59
Metacognitive therapy in treatment-resistant psychosis: a multiple-baseline study.
Hutton, P., Morrison, A. P., Wardle, M., & Wells, A. (2014) · Behavioural and Cognitive Psychotherapy · doi:10.1017/s1352465812001026 · Cited by 58
“…(Lepping, Sambhi, Whittington, Lane and Poole, 2011; Leucht, Arbter, Engel, Kissling and Davis, 2009a; Rattehalli, Jayaram and Smith, 2010), while very high rates of drop-out from short and long-term clinical trials suggest low acceptability (Leucht et al., 2009a; Lieberman et al., 2005).”
BackgroundAmericans' Attitudes Toward Psychiatric Medications: 1998–2006
Mojtabai, R. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.8.1015 · Cited by 57
Woolley, S. B., Cardoni, A. A., & Goethe, J. W. (2009) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.12.1408 · Cited by 52
Yilmaz, Z., Zai, C. C., Hwang, R., Mann, S., Arenovich, T., Remington, G., & Daskalakis, Z. J. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.06.027 · Cited by 52
Cholinergic Circuits and Signaling in the Pathophysiology of Schizophrenia
Berman, J. A., Talmage, D. A., & Role, L. W. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78007-2 · Cited by 47
Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.
Vinkers, C. H., Kupka, R. W., Penninx, B. W., Ruhé, H. G., van Gaalen, J. M., van Haaren, P. C. F., Schellekens, A. F. A., Jauhar, S., Ramos-Quiroga, J. A., Vieta, E., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02445-4 · Cited by 51
Haro, J. M., Novick, D., Belger, M., & Jones, P. B. (2006) · European Psychiatry · doi:10.1016/j.eurpsy.2005.12.001 · Cited by 49
Mental health professionals’ views and experiences of antipsychotic reduction and discontinuation
Cooper, R. E., Hanratty, É., Morant, N., & Moncrieff, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218711 · Cited by 49
Geerts, P., Martinez, G., & Schreiner, A. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-58 · Cited by 48
Fleiner, T., Dauth, H., Gersie, M., Zijlstra, W., & Haussermann, P. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0289-z · Cited by 48
McGrath, L. M., Cornelis, M. C., Lee, P. H., Robinson, E. B., Duncan, L. E., Barnett, J. H., Huang, J., Gerber, G., Sklar, P., Sullivan, P., et al. (2013) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32190 · Cited by 48
In vitro effects of antipsychotics on mitochondrial respiration
Cikánková, T., Fišar, Z., Bakhouche, Y., Ľupták, M., & Hroudová, J. (2019) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-019-01665-8 · Cited by 44
Smith, R. C., Leucht, S., & Davis, J. M. (2019) · Psychopharmacology · doi:10.1007/s00213-018-5133-z · Cited by 41
Bolding, M. S., White, D. M., Hadley, J. A., Weiler, M., Holcomb, H. H., & Lahti, A. C. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00105 · Cited by 41
Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment.
Modestin, J., Wehrli, M. V., Stephan, P. L., & Agarwalla, P. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.10.018 · Cited by 38
De, R., Smith, E. C. C., Navagnanavel, J., Au, E., Maksyutynska, K., Papoulias, M., Singh, R., Panganiban, K. J., Humber, B., Mohr, G. H., et al. (2025) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13758 · Cited by 39
Tonarelli, S. B., & Pasillas, R. (2016) · Journal of psychiatry · doi:10.4172/2378-5756.1000366 · Cited by 38
Implications of clinical trial design on sample size requirements
Leon, A. C. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn035 · Cited by 35
Computational approaches to schizophrenia: A perspective on negative symptoms
Deserno, L., Heinz, A., & Schlagenhauf, F. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2016.10.004 · Cited by 31
Alene, M., Wiese, M. D., Angamo, M. T., Bajorek, B. V., Yesuf, E. A., & Wabe, N. T. (2012) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-12-10 · Cited by 34
Dichotomizing rating scale scores in psychiatry: a bad idea?
Purgato, M., & Barbui, C. (2013) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796012000613 · Cited by 33
Matsuoka, T., Narumoto, J., Shibata, K., Okamura, A., Nakamura, K., Okuyama, C., Nishimura, T., & Fukui, K. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000295115 · Cited by 32
The treatment of psychotic major depression: Is there a role for adjunctive psychotherapy?
Gaudiano, B. A., Miller, I. W., & Herbert, J. D. (2007) · Psychotherapy and Psychosomatics · doi:10.1159/000104703 · Cited by 31
Khan, W. U., Ghazala, Z., Brooks, H. J., Subramaniam, P., Mulsant, B. H., Kumar, S., Voineskos, A. N., Blumberger, D. M., Kern, R. S., & Rajji, T. K. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa093 · Cited by 27
Mohamed, S., Rosenheck, R., He, H., & Yuping, N. (2014) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-014-0824-1 · Cited by 26
Self-citationExperiencing antipsychotic discontinuation: results from a survey of Australian consumers
Salomon, C., Hamilton, B., & Elsom, S. (2014) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/jpm.12178 · Cited by 25
Zhou, Y., Rosenheck, R., Mohamed, S., Ning, Y., & He, H. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.01.036 · Cited by 23
Self-citationBaptista, P. P. A., de Senna, P. N., Paim, M. F., Saur, L., Blank, M., do Nascimento, P., Ilha, J., Vianna, M. R. M., Mestriner, R. G., Achaval, M., et al. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.12.020 · Cited by 23
Roberts, E., Jones, L., Blackman, A., Dewhurst, T., Matcham, F., Kan, C., Mustafa, O., Thomas, T., Siddiqi, N., Ismail, K., et al. (2017) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2017.01.003 · Cited by 23
Preventing discrimination based on psychiatric risk biomarkers
Brannan, C., Foulkes, A. L., & Lázaro‐Muñoz, G. (2019) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32629 · Cited by 22
Leverage, the Treatment Relationship, and Treatment Participation
McNiel, D. E., Gormley, B., & Binder, R. L. (2013) · Psychiatric Services · doi:10.1176/appi.ps.201200368 · Cited by 21
Risk of readmission in compulsorily and voluntarily admitted patients
Valevski, A., Olfson, M., Weizman, A., & Shiloh, R. (2007) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-007-0243-7 · Cited by 21
del Barrio, L. R., Cyr, C., Benisty, L., & Richard, P. (2013) · Ciência & Saúde Coletiva · doi:10.1590/s1413-81232013001000012 · Cited by 21
Pragmatic design in randomized controlled trials
Purgato, M., Barbui, C., Stroup, S., & Adams, C. (2015) · Psychological Medicine · doi:10.1017/s0033291714001275 · Cited by 19
Halene, T. B., Kozlenkov, A., Jiang, Y., Mitchell, A. C., Javidfar, B., Dincer, A., Park, R., Wiseman, J., Croxson, P. L., Giannaris, E. L., et al. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2015.12.016 · Cited by 18
Valenstein, M. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1484 · Cited by 15
Adverse effects of antipsychotic drugs: survey of doctors’ versus patients’ perspective.
Nosè, M., Mazzi, M. A., Esposito, E., Bianchini, M., Petrosemolo, P., Ostuzzi, G., Tansella, M., & Barbui, C. (2012) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-010-0320-1 · Cited by 16
Politis, A. M., Papadimitriou, G. N., Theleritis, C. G., Psarros, C., & Soldatos, C. R. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.03.011 · Cited by 15
The biology of mental disorders: progress at last
Hyman, S. E. (2023) · Daedalus · doi:10.1162/daed_a_02038 · Cited by 15
Lui, S. S. Y., Lam, J. P. Y., Lam, J. W. S., Chui, W. W. H., Mui, J. H. C., Siu, B. W. M., Cheng, K. M., Cheung, E. F. C., & Chan, R. C. K. (2021) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2021.102644 · Cited by 13
Bahji, A., & Delva, N. (2022) · Journal of Medical Ethics · doi:10.1136/medethics-2020-107133 · Cited by 12
Balzan, R. P., & Galletly, C. (2015) · Frontiers in Psychology · doi:10.3389/fpsyg.2015.00967 · Cited by 12
Sudden Cardiac Death in People With Schizophrenia
Paratz, E. D., van Heusden, A., Zentner, D., Morgan, N., Smith, K., Thompson, T., James, P., Connell, V., Pflaumer, A., Semsarian, C., et al. (2023) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2023.01.026 · Cited by 10
Kishi, T., Matsuda, Y., Sakuma, K., Okuya, M., & Iwata, N. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.08.003 · Cited by 8
Antipsychotic use in the elderly: what doctors say they do, and what they do
Tiller, J., Ames, D., Brodaty, H., Byrne, G., Chawla, S., Halliday, G., Snowdon, J., Hepworth, G., McArdle, P., & Schweitzer, I. (2008) · Australasian Journal on Ageing · doi:10.1111/j.1741-6612.2008.00308.x · Cited by 8
N-3 Fatty Acids for Hypertriglyceridemia in Patients Taking Second-Generation Antipsychotics
Fetter, J. C., Brunette, M., & Green, A. I. (2013) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.febr.012513 · Cited by 7
Metadata
- Authors
- Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., Severe, J., & Hsiao, J. K.
- Affiliations
- New York State Psychiatric Institute (US)
- Duke University (US)
- Yale University (US)
- University of North Carolina at Chapel Hill (US)
- National Institutes of Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-09-22
- Volume
- 353
- Issue
- 12
- Pages
- 1209-1223
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2159155203
- Cited by
- 5,892
- References
- 32
- Citations by year
- 2026: 95 · 2025: 89 · 2024: 135 · 2023: 129 · 2022: 191 · 2021: 166 · 2020: 338 · 2019: 207 · 2018: 211 · 2017: 220 · 2016: 231 · 2015: 277 · 2014: 325 · 2013: 361 · 2012: 379
- FWCI
- 258.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Case Western Reserve University
- Foundation of Hope for Research and Treatment of Mental Illness
- Otsuka Pharmaceutical
- National Institutes of Health (n01mh90001-21-0-0)
- University of North Carolina at Chapel Hill
- National Institute of Mental Health (N01 MH90001, MH90001)
- Janssen Pharmaceuticals
- School of Medicine, University of North Carolina at Chapel Hill
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- schizophrenia, antipsychotic drugs, atypical antipsychotics, typical antipsychotics, perphenazine, olanzapine, quetiapine, risperidone, ziprasidone, treatment discontinuation, treatment efficacy, adverse effects, weight gain, metabolic effects, extrapyramidal symptoms, chronic schizophrenia, double-blind comparison, long-term treatment
- MeSH terms
- Quetiapine Fumarate, Olanzapine, Adult, Benzodiazepines, Chronic Disease, Dibenzothiazepines, Double-Blind Method, Female, Humans, Lipids, Male, Patient Compliance, Perphenazine, Piperazines, Schizophrenia, Thiazoles, Antipsychotic Agents, Weight Gain, Proportional Hazards Models, Treatment Outcome, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
